アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

quality care products, llc - diclofenac epolamine (unii: x5f8ekl9zg) (diclofenac - unii:144o8ql0l1) - diclofenac epolamine 180 mg in 14 g - flector® patch is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. flector patch is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product [see warnings and precautions (5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [see warnings and precautions (5.7, 5.8) ] - in the setting of coronary artery bypass graft (cabg) surgery [see warnings and precautions (5.1) ] - flector patch is contraindicated for use on non-intact or damaged skin resulting from any etiology, including exudative dermatitis, eczema, infection lesions, burns or wounds. risk summary published literature reports that use of nsaids, including flector patch, after 30 weeks' gestation increases the risk of premature closu

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

global treat srl - white petrolatum 21.3% wt/wt, lanolin 21.25% wt/wt, hard fat 42.6% wt/wt, camphor 2.5% wt/wt - protectant protectant protectant analgesic - helps relieve itching and discomfort associated with hemorrhoids and anorectal disorders - temporarily relieves pain associated with anorectal inflammation and inflamed hemorrhoidal tissues - may provide cooling sensation - do not use for more than consecutive 30 days - when using this product do not exceed the recommended daily dosage, unless directed by a doctor - bleeding occurs - condition worsens or does not improve within seven days - signs of a local infection appear - certain person can develop allergic reactions to ingredients in this product. if the symptom being treated does not subside of if redness, irritation, swelling, pain, and or other symptoms develop or increase, discontinue use and consult a doctor.

欧州連合 - 英語 - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

マルタ - 英語 - Malta Medicines Authority

dompe farmaceutici spa via san martino 12, 20122, milan, italy - carbocisteine - powder for oral solution - carbocisteine 1.35 g - cough and cold preparations

マルタ - 英語 - Malta Medicines Authority

doc generici srl via turati, 40-20121, milano, italy - zonisamide - hard capsule - zonisamide 25 mg - antiepileptics

マルタ - 英語 - Malta Medicines Authority

doc generici srl via turati, 40-20121, milano, italy - zonisamide - hard capsule - zonisamide 50 mg - antiepileptics

マルタ - 英語 - Malta Medicines Authority

doc generici srl via turati, 40-20121, milano, italy - zonisamide - hard capsule - zonisamide 100 mg - antiepileptics

マルタ - 英語 - Malta Medicines Authority

doc generici srl via turati, 40-20121, milano, italy - dutasteride, tamsulosin hydrochloride - hard capsule - tamsulosin hydrochloride 0.4 mg dutasteride 0.5 mg - urologicals

マルタ - 英語 - Malta Medicines Authority

chiesi farmaceutici s.p.a via palermo 26/a, 43122 parma, italy - phospholipids - endotracheopulmonary instillation, suspension - phospholipids 80 mg/ml - other respiratory system products

イスラエル - 英語 - Ministry of Health

kamada ltd, israel - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - pressurised solution - formoterol fumarate dihydrate 6 mcg/actuation; beclometasone dipropionate anhydrous 200 mcg/actuation - formoterol and beclometasone - foster 200/6 is indicated in the regular treatment of asthma in adults where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.